𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Nectin-2 is a potential target for antibody therapy of breast and ovarian cancers

✍ Scribed by Tsutomu Oshima, Shuji Sato, Junichi Kato, Yuki Ito, Takahiro Watanabe…

Book ID
120688456
Publisher
BioMed Central
Year
2013
Tongue
English
Weight
656 KB
Volume
12
Category
Article
ISSN
1476-4598

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The differentiation antigen NY-BR-1 is a
The differentiation antigen NY-BR-1 is a potential target for antibody-based therapies in breast cancer
✍ Inka Seil; Claudia Frei; Holger Sültmann; Shirley K. Knauer; Knut Engels; Elke J 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 French ⚖ 976 KB

## Abstract Antibody‐based cancer immunotherapy relies on the identification and characterization of target antigens and the development of potent antibodies recognizing the target. Here we report the expression analysis and molecular characterization of the differentiation antigen NY‐BR‐1, which w

HMGA2 gene is a promising target for ova
HMGA2 gene is a promising target for ovarian cancer silencing therapy
✍ Anastasia Malek; Elena Bakhidze; Aurelia Noske; Christine Sers; Achim Aigner; Re 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 French ⚖ 662 KB

## Abstract Ovarian cancer is one of the most lethal gynecological malignancies and the small success rate of routine therapeutic methods justifies efforts to develop new approaches. Evaluation of targets for effective inhibition of ovarian cancer cell growth should precipitate clinical application

Clinical trials and future potential of
Clinical trials and future potential of targeted therapy for ovarian cancer
✍ Itamochi, Hiroaki; Kigawa, Junzo 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 274 KB

Ovarian cancer is the leading cause of death in women with gynecological cancer. Most patients are diagnosed at an advanced stage with a poor prognosis. Currently, surgical tumor debulking followed by chemotherapy based on platinum and taxane is the standard treatment for advanced disease. However,